Hastings David C
CIK 0001237401
Chief Financial OfficerDirector
Filings
13
Latest Jan 12, 2026
Issuers covered
4
Showing
13 of 13
Page 1
Track record
2 of 2 open-market trades scored (100% price coverage). Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 2 | 0% | -7.1% | -7.1% | -0.3% | -13.9% |
| 90 days | 2 | 0% | -8.5% | -8.5% | -4.5% | -12.6% |
| 180 days | 2 | 50% | -28.9% | -28.9% | +0.6% | -58.4% |
| 365 days | 2 | 0% | -26.6% | -26.6% | -15.5% | -37.8% |
Issuers
Companies where Hastings David C has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| ABUS | Arbutus Biopharma Corp | 5 | Feb 19, 2025 |
| SCYX | Scynexis Inc | 5 | Jun 30, 2025 |
| ETTX | Entasis Therapeutics Holdings Inc. | 2 | Feb 15, 2022 |
| TRVI | Trevi Therapeutics, Inc. | 1 | Jan 12, 2026 |
All filings
13 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|